29 In clinical practice, it is crucial to select a GLP-1RA with cardiovascular efficacy, good glucose lowering and weight loss according to the patients condition and needs
While effective and free of hepatotoxicity, high rates of nausea (70%) and vomiting (67-69%) pose challenges for global studies
There is, however, another higher-dose semaglutide medication that is approved for weight loss by the name of Wegovy
Individual GLP-1 treatment results may vary from person to person
On the other hand, Wegovy, which contains semaglutide, has demonstrated average weight losses of around 14.9% after 68 weeks
The latest clinical report from Prime, The evolution of GLP-1s, delves into some of the latest insights, empowering health plans, pharmacies and members with recent research, data, trends and forecasting for these medications, which are approved to treat type 2 diabetes, obesity and cardiovascular conditions